- Home
- » Tags
- » Delafloxacin
Top View
- Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
- New-Generation Antibiotics for Treatment of Gram-Positive Infections: a Review with Focus on Endocarditis and Osteomyelitis
- Quinolone Antibiotics
- Delafloxacin Poster.Indd 1 4/6/17 1:52 PM
- New Perspectives on Antibacterial Drug Research
- Development of New Novel Bacterial Topoisomerase Inhibitors As Promising Antibiotics with a 5-Amino-1,3-Dioxane Linker Moiety DI
- Antibiotics Update
- BAXDELA (Delafloxacin) Tablets, for Oral Use (Egfr)(Ml/Min/1.73M2)A BAXDELA (Delafloxacin) for Injection, for Intravenous Use B Initial U.S
- Guide to Antimicrobial Chemotherapy (PDF)
- 2019 Antibacterial Agents in Clinical Development
- New Drug Evaluation Monograph Template
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus Aureus
- Quofenix, INN-Delafloxacin
- Antibiotics in the Clinical Pipeline in October 2019
- New ATC Codes and New Ddds to Be Included in the 2019 Edition of the ATC/DDD Index Are Also Enclosed
- Rare-Earth Metal Complexes of the Antibacterial Drug Oxolinic Acid: Synthesis, Characterization, DNA/Protein Binding and Cytotoxicity Studies
- Novel Antibiotic Treatment for Skin and Soft Tissue Infection
- Amc Data 2011–2017
- BAXDELA (Delafloxacin) Tablets, for Oral Use 30-89 No Dosage No Dosage BAXDELA (Delafloxacin) for Injection, for Intravenous Use Adjustment Adjustment Initial U.S
- Antibacterial: a Review
- BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
- Recommendations of the SEC (Antimicrobial & Antiviral)
- Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections: Focus on Intravenous Delafloxacin
- Your 2021 Western Health Advantage 3-Tier Preferred Drug List
- COMPARED to MOXIFLOXACIN (MOX) in PATIENTS with COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) Idweek 2019TM Robert A
- 208610Orig1s000 208611Orig1s000
- Antimicrobial Medicines Consumption in Eastern Europe and Central Asia – an Updated Cross-National Study and Assessment of Quantitative Metrics for Policy Action
- Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections: Focus on Intravenous Delafloxacin
- Delafloxacin (Baxdela) Reference Number: ERX.NPA.54 Effective Date: 08.01.17 Revision Log Last Review Date: 11.17
- Quinolones a Systematic Quest
- The Enlarging Threat of Antibiotic Resistance
- Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties
- Fluoroquinolones, Oral Therapeutic Class Review (TCR) June 18, 2013 Please Note: This Clinical Document Has Been Retired
- Quinolone Allergy
- Fluoroquinolones
- Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
- Nephropharmacology for the Clinician
- 09 – Core Concepts: Antibacterial Drugs II Speaker: Helen Boucher, MD
- Delafloxacin Activity Tested Against Bacterial Pathogens From
- Antimicrobial Medicines Consumption in Eastern Europe and Central Asia – an Updated Cross-National Study and Assessment of Quantitative Metrics for Policy Action
- Delafloxacin
- Table of Contents